Mucosal leishmaniasis: description of case management approaches and analysis of risk factors for treatment failure in a cohort of 140 patients in Brazil.
about
Diagnosis and Treatment of Leishmaniasis: Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH).Interleukin 32γ (IL-32γ) is highly expressed in cutaneous and mucosal lesions of American Tegumentary Leishmaniasis patients: association with tumor necrosis factor (TNF) and IL-10.Facial structure alterations and abnormalities of the paranasal sinuses on multidetector computed tomography scans of patients with treated mucosal leishmaniasis.Mucosal leishmaniasis and abnormalities on computed tomographic scans of paranasal sinusesOral manifestations in the American tegumentary leishmaniasis.An update on pharmacotherapy for leishmaniasisSpecies-directed therapy for leishmaniasis in returning travellers: a comprehensive guideAmerican tegumentary leishmaniasis and HIV-AIDS association in a tertiary care center in the Brazilian AmazonCutaneous leishmaniasis: recent developments in diagnosis and managementCan we use a lower dose of liposomal amphotericin B for the treatment of mucosal American leishmaniasis?Cytokines and microbicidal molecules regulated by IL-32 in THP-1-derived human macrophages infected with New World Leishmania species.Efficacy and Safety of Liposomal Amphotericin B for the Treatment of Mucosal Leishmaniasis from the New World: A Retrospective StudyPrimary oral Penicillium marneffei infection diagnosed by PCR-based molecular identification and transmission electron microscopic observation from formalin-fixed paraffin-embedded tissuesTreatment failure and miltefosine susceptibility in dermal leishmaniasis caused by Leishmania subgenus Viannia species.Cutaneous and mucocutaneous leishmaniasis: emerging therapies and progress in disease management.Local or systemic treatment for New World cutaneous leishmaniasis? Re-evaluating the evidence for the risk of mucosal leishmaniasis.Therapeutic options for old world cutaneous leishmaniasis and new world cutaneous and mucocutaneous leishmaniasis.LeishMan recommendations for treatment of cutaneous and mucosal leishmaniasis in travelers, 2014.Development of an ex vivo lymph node explant model for identification of novel molecules active against Leishmania major.Efficacy of azole therapy for tegumentary leishmaniasis: A systematic review and meta-analysis.Polymerase chain reaction-miniexon: a promising diagnostic method for mucocutaneous leishmaniasis.A case of mucocutaneous leishmaniasis diagnosed by serology.Genetic polymorphism in Leishmania (Viannia) braziliensis detected in mucosal leishmaniasis of HIV-infected and non-HIV-infected patients.Treatment of mucosal leishmaniasis with amphotericin B lipid complex (ABLC)
P2860
Q30275257-C8294E48-936B-4D2E-9F3E-9433839A1DB3Q33633481-29C731A4-5F25-49C0-BECD-0D8F3668EB55Q33981782-C26BCA1E-AAB4-4D55-B273-F45CC00B849AQ34087321-F20B6748-7D43-407A-BB82-9C653DEFE32DQ34489065-7E0CA01F-BA7E-4672-9908-282B120B166AQ34945204-822B3A45-691B-44E2-9F63-59D1BF1CA52CQ35160905-6626A4A5-2A2B-460C-88CD-38A700BF2601Q35186855-88F43528-93EE-4105-B537-990932DC7C82Q35187729-98148DED-E2E2-46A3-B8A7-FB79DE35AB45Q35494361-799141BD-07C5-4319-9CA1-3CB0D919132FQ36291428-61914866-9604-4D5C-9511-CF06B83DB2B1Q36359258-9BC8CA00-958C-42CD-8D0F-5631EBF4AF5FQ37454211-8C2F5109-EAE9-4A05-87F8-EE64CE1C8AC0Q37544280-AC757D68-FB7B-4B0D-A03C-09F6ADEB8A55Q37693923-6FD88EE0-B851-4AA5-929B-ED31E80DAF66Q38136837-23C7A658-5824-4C97-9570-6D4F27779B5DQ38156421-A4A3B4B0-41BE-413E-A471-DD27EF135DF9Q38205451-E409F89E-0DE3-40D3-9443-CE4B08F93739Q39348237-E1F3B23C-14CB-406E-8860-B73649362E4BQ42708364-28F09EB7-EEFF-434F-9834-9AC12124378DQ46657006-CF0599E0-9F34-4289-8765-159BEAC4EFEFQ52776218-36DFA917-4811-4F08-B9A1-1DCFEC3E3174Q54293575-B0949564-1F80-42F2-9D5B-E9813FFBFDC2Q59139032-FCBAB546-C753-4A7F-B91E-23E470FCC6EF
P2860
Mucosal leishmaniasis: description of case management approaches and analysis of risk factors for treatment failure in a cohort of 140 patients in Brazil.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Mucosal leishmaniasis: descrip ...... ort of 140 patients in Brazil.
@en
Mucosal leishmaniasis: descrip ...... ort of 140 patients in Brazil.
@nl
type
label
Mucosal leishmaniasis: descrip ...... ort of 140 patients in Brazil.
@en
Mucosal leishmaniasis: descrip ...... ort of 140 patients in Brazil.
@nl
prefLabel
Mucosal leishmaniasis: descrip ...... ort of 140 patients in Brazil.
@en
Mucosal leishmaniasis: descrip ...... ort of 140 patients in Brazil.
@nl
P2093
P2860
P1476
Mucosal leishmaniasis: descrip ...... ort of 140 patients in Brazil.
@en
P2093
M I Duarte
R Abegão de Camargo
P2860
P304
P356
10.1111/J.1468-3083.2009.03238.X
P577
2009-05-04T00:00:00Z